BioNote, Inc. (KRX:377740)
South Korea
· Delayed Price · Currency is KRW 4,535.00
+35.00 (0.78%)
Last updated: Apr 17, 2025
BioNote Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 102,780 | 90,081 | 479,657 | 622,355 | 631,505 | Upgrade
|
| Other Revenue | - | 0 | -0 | -0 | - | Upgrade
|
| Revenue | 102,780 | 90,081 | 479,657 | 622,355 | 631,505 | Upgrade
|
| Revenue Growth (YoY) | 14.10% | -81.22% | -22.93% | -1.45% | 1476.89% | Upgrade
|
| Cost of Revenue | 51,807 | 101,739 | 139,186 | 110,352 | 51,950 | Upgrade
|
| Gross Profit | 50,973 | -11,659 | 340,471 | 512,003 | 579,554 | Upgrade
|
| Selling, General & Admin | 22,868 | 22,787 | 31,519 | 24,340 | 13,102 | Upgrade
|
| Research & Development | 13,577 | 13,405 | 16,138 | 11,300 | 7,612 | Upgrade
|
| Other Operating Expenses | 265.78 | 168.12 | 176.92 | 345.29 | 45.46 | Upgrade
|
| Operating Expenses | 38,756 | 35,510 | 45,062 | 43,255 | 21,523 | Upgrade
|
| Operating Income | 12,218 | -47,168 | 295,410 | 468,748 | 558,031 | Upgrade
|
| Interest Expense | -233.55 | -602.82 | -84.44 | -44.25 | -172.63 | Upgrade
|
| Interest & Investment Income | 20,059 | 24,630 | 9,715 | 873.63 | 37.56 | Upgrade
|
| Earnings From Equity Investments | 18,910 | - | -147,264 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 40,603 | 10,164 | 24,512 | 24,159 | -5,726 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,096 | 420.84 | -296.63 | -123.11 | -75.83 | Upgrade
|
| EBT Excluding Unusual Items | 92,653 | -12,556 | 181,992 | 493,612 | 552,094 | Upgrade
|
| Gain (Loss) on Sale of Investments | -14,511 | -88,791 | 219,374 | 376,239 | 143,115 | Upgrade
|
| Gain (Loss) on Sale of Assets | 20.25 | 265.2 | 13,412 | 33.39 | -11.45 | Upgrade
|
| Asset Writedown | -4,835 | -8,409 | - | - | - | Upgrade
|
| Pretax Income | 73,327 | -109,491 | 414,778 | 869,885 | 695,198 | Upgrade
|
| Income Tax Expense | 18,065 | -88,994 | 106,980 | 193,284 | 166,969 | Upgrade
|
| Net Income | 55,261 | -20,497 | 307,798 | 676,601 | 528,229 | Upgrade
|
| Net Income to Common | 55,261 | -20,497 | 307,798 | 676,601 | 528,229 | Upgrade
|
| Net Income Growth | - | - | -54.51% | 28.09% | 2462.62% | Upgrade
|
| Shares Outstanding (Basic) | 102 | 102 | 94 | 94 | 94 | Upgrade
|
| Shares Outstanding (Diluted) | 102 | 102 | 94 | 94 | 94 | Upgrade
|
| Shares Change (YoY) | -0.08% | 8.16% | 0.64% | 0.14% | 11.08% | Upgrade
|
| EPS (Basic) | 542.36 | -200.99 | 3277.21 | 7232.04 | 5646.12 | Upgrade
|
| EPS (Diluted) | 542.00 | -201.00 | 3264.00 | 7222.00 | 5646.00 | Upgrade
|
| EPS Growth | - | - | -54.81% | 27.91% | 2206.94% | Upgrade
|
| Free Cash Flow | 47,454 | -8,156 | 206,834 | 485,966 | 213,228 | Upgrade
|
| Free Cash Flow Per Share | 465.74 | -79.98 | 2193.65 | 5186.94 | 2279.15 | Upgrade
|
| Gross Margin | 49.59% | -12.94% | 70.98% | 82.27% | 91.77% | Upgrade
|
| Operating Margin | 11.89% | -52.36% | 61.59% | 75.32% | 88.37% | Upgrade
|
| Profit Margin | 53.77% | -22.75% | 64.17% | 108.72% | 83.65% | Upgrade
|
| Free Cash Flow Margin | 46.17% | -9.05% | 43.12% | 78.09% | 33.77% | Upgrade
|
| EBITDA | 20,404 | -38,962 | 301,861 | 472,854 | 559,918 | Upgrade
|
| EBITDA Margin | 19.85% | -43.25% | 62.93% | 75.98% | 88.66% | Upgrade
|
| D&A For EBITDA | 8,186 | 8,206 | 6,451 | 4,106 | 1,887 | Upgrade
|
| EBIT | 12,218 | -47,168 | 295,410 | 468,748 | 558,031 | Upgrade
|
| EBIT Margin | 11.89% | -52.36% | 61.59% | 75.32% | 88.37% | Upgrade
|
| Effective Tax Rate | 24.64% | - | 25.79% | 22.22% | 24.02% | Upgrade
|
| Advertising Expenses | 2,422 | 2,414 | 2,332 | 1,063 | 540.13 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.